

(43) International Publication Date
26 November 2009 (26.11.2009)(10) International Publication Number
WO 2009/142569 A1

(51) International Patent Classification:

C07D 231/56 (2006.01) **C07D 401/14** (2006.01)
A61K 31/416 (2006.01) **C07D 403/10** (2006.01)
A61K 31/422 (2006.01) **C07D 403/12** (2006.01)
A61K 31/4439 (2006.01) **C07D 407/14** (2006.01)
A61K 31/444 (2006.01) **C07D 409/12** (2006.01)
A61P 11/00 (2006.01) **C07D 409/14** (2006.01)
A61P 29/00 (2006.01) **C07D 413/12** (2006.01)
C07D 401/12 (2006.01)

(21) International Application Number:

PCT/SE2009/000265

(22) International Filing Date:

20 May 2009 (20.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/054,616	20 May 2008 (20.05.2008)	US
61/080,312	14 July 2008 (14.07.2008)	US
61/144,776	15 January 2009 (15.01.2009)	US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAYER SCHERING PHARMA AG** [DE/DE]; Müllerstrasse 178, D-13353 Berlin (DE). **BERGER, Markus** [DE/DE]; Bayer Schering Pharma AG, Müllerstrasse 178, D-13353 Berlin (DE). **DAHMEN, Jan** [SE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE). **EDMAN Karl** [SE/SE]; AstraZeneca R&D Mölndal, S-431 83 Mölndal (SE). **HANSSON, Thomas** [SE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE). **HEMMERLING, Martin** [DE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE).

HOSSAIN, Nafizal [SE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE). **JOHANSSON, Henrik** [SE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE). **LEP-ISTÖ, Matti** [SE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE). **NILSSON, Stinabritt** [SE/SE]; AstraZeneca R&D Lund, S-221 87 Lund (SE). **REHWINKEL, Hartmut** [DE/DE]; Bayer Schering Pharma AG, Müllerstrasse 178, D-13353 Berlin (DE).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES



(57) Abstract: A compound of formula Ia: Formula (Ia) The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.